Replies to post #98585 on Biotech Values

[DewDiligence]

Doesn't the emergence of an oral MS agent also make a favorable Markman ruling for MNTA’s generic copaxone less important?

Yes, to a small degree. However, Copaxone isn’t going to disappear; it will surely retain enough sales that a sole US generic for Copaxone would be one of the largest-selling generic drugs of all time and a very lucrative product for MNTA.